Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VH4004280 in Healthy Adults
NCT05163522Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Dec 2021
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH-4004280 in human immunodeficiency virus infection (HIV) (11 arms), sponsored by ViiV Healthcare. Primary endpoints: Number of Participants With Any Adverse Events (AEs) and by Severity, Number of Participants Discontinuing Treatment Due to AEs and 7 more. Started Dec 2021; status: completed.
02
Drugs
VH-4004280
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05163522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163522.